# Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

> **NCT04872478** · PHASE1 · RECRUITING · sponsor: **Meryx, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Mixed Phenotype Acute Leukemia

## Interventions

- **DRUG:** MRX-2843

## Key facts

- **NCT ID:** NCT04872478
- **Lead sponsor:** Meryx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04872478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04872478, "Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04872478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*